The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Elranatamab vs real-world treatments in triple-class refractory myeloma: insights from MagnetisMM-3
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses a comparative analysis of elranatamab against real-world (RW) regimens for patients with triple-class refractory multiple myeloma. Findings revealed improvements in progression-free survival (PFS), duration of response (DoR), and overall survival (OS) in patients treated with elranatamab compared with treatments currently used in RW clinical practice. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
